Published in Proc Natl Acad Sci U S A on May 26, 2005
Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol (2006) 4.02
Human C-reactive protein does not promote atherosclerosis in transgenic rabbits. Circulation (2009) 2.83
Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J Clin Immunol (2007) 2.03
Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ Res (2005) 1.91
Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction. Circulation (2011) 1.77
The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor κ light-chain enhancer of activated B cells (NF-κB) in mice. Hepatology (2011) 1.71
Effects of human C-reactive protein on pathogenesis of features of the metabolic syndrome. Hypertension (2011) 1.71
C-reactive protein, inflammatory conditions, and cardiovascular disease risk. Am J Med (2007) 1.64
The evolving role of C-reactive protein in atherothrombosis. Clin Chem (2008) 1.48
Inflammatory processes in cardiovascular disease: a route to targeted therapies. Nat Rev Cardiol (2016) 1.46
C-reactive protein in atherosclerotic lesions: its origin and pathophysiological significance. Am J Pathol (2005) 1.37
Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia. Proc Natl Acad Sci U S A (2007) 1.37
The connection between C-reactive protein and atherosclerosis. Ann Med (2008) 1.29
Human C-reactive protein induces endothelial dysfunction and uncoupling of eNOS in vivo. Atherosclerosis (2009) 1.26
Pentraxins: structure, function, and role in inflammation. ISRN Inflamm (2013) 1.23
From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection. Circ Res (2016) 1.22
C-reactive protein-bound enzymatically modified low-density lipoprotein does not transform macrophages into foam cells. J Immunol (2008) 1.21
The innate immune response to products of phospholipid peroxidation. Biochim Biophys Acta (2012) 1.20
Pattern recognition by pentraxins. Adv Exp Med Biol (2009) 1.19
No reduction of atherosclerosis in C-reactive protein (CRP)-deficient mice. J Biol Chem (2010) 1.11
Exaggerated neointima formation in human C-reactive protein transgenic mice is IgG Fc receptor type I (Fc gamma RI)-dependent. Am J Pathol (2007) 1.10
Increased aortic atherosclerotic plaque development in female apolipoprotein E-null mice is associated with elevated thromboxane A2 and decreased prostacyclin production. J Physiol Pharmacol (2010) 1.03
Role of the property of C-reactive protein to activate the classical pathway of complement in protecting mice from pneumococcal infection. J Immunol (2006) 1.01
C-reactive protein-mediated vascular injury requires complement. Arterioscler Thromb Vasc Biol (2010) 0.96
C-reactive protein is elevated 30 years after eclamptic pregnancy. Hypertension (2008) 0.90
Linking inflammation and thrombosis: Role of C-reactive protein. World J Cardiol (2010) 0.89
Atherosclerosis-related functions of C-reactive protein. Cardiovasc Hematol Disord Drug Targets (2010) 0.87
Exposing a hidden functional site of C-reactive protein by site-directed mutagenesis. J Biol Chem (2011) 0.86
Recognition functions of pentameric C-reactive protein in cardiovascular disease. Mediators Inflamm (2014) 0.86
C-reactive protein and atherogenesis: new insights from established animal models. Am J Pathol (2005) 0.86
Neointimal formation is reduced after arterial injury in human crp transgenic mice. Atherosclerosis (2008) 0.83
Does C-reactive protein contribute to atherothrombosis via oxidant-mediated release of pro-thrombotic factors and activation of platelets? Front Physiol (2012) 0.82
Isolation and characterization of pharmaceutical grade human pentraxins, serum amyloid P component and C-reactive protein, for clinical use. J Immunol Methods (2012) 0.81
The macrophage LBP gene is an LXR target that promotes macrophage survival and atherosclerosis. J Lipid Res (2014) 0.80
The Dual Complexity of PTX3 in Health and Disease: A Balancing Act? Trends Mol Med (2016) 0.79
Solubilization and purification of recombinant modified C-reactive protein from inclusion bodies using reversible anhydride modification. Biophys Rep (2015) 0.78
Mutations of C-reactive protein (CRP) -286 SNP, APC and p53 in colorectal cancer: implication for a CRP-Wnt crosstalk. PLoS One (2014) 0.78
Could antibodies to C-reactive protein link inflammation and cardiovascular disease in patients with systemic lupus erythematosus? Ann Rheum Dis (2007) 0.78
Plasma Levels of Endothelial Microparticles Bearing Monomeric C-reactive Protein are Increased in Peripheral Artery Disease. J Cardiovasc Transl Res (2016) 0.77
Animal models of C-reactive protein. Mediators Inflamm (2014) 0.77
Fcγ receptors and ligands and cardiovascular disease. Circ Res (2015) 0.77
Monomeric C-reactive protein and inflammatory injury in myocardial infarction. Cardiovasc Res (2012) 0.76
Pentraxins in the activation and regulation of innate immunity. Immunol Rev (2016) 0.76
The immunology of atherosclerosis. Nat Rev Nephrol (2017) 0.75
Effects of antisense oligonucleotides against C-reactive protein on the development of atherosclerosis in WHHL rabbits. Mediators Inflamm (2014) 0.75
Study of High Sensitive C-Reactive Protein (HS-CRP) After Cardiac Rehabilitation Program in Patients Undergoing Isolated CABG. Int J Biomed Sci (2016) 0.75
Atherosclerosis--an inflammatory disease. N Engl J Med (1999) 59.28
Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest (2003) 41.22
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med (1997) 18.85
C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med (2004) 15.30
C-reactive protein: a critical update. J Clin Invest (2003) 11.77
The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med (1994) 8.10
Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA (1998) 7.67
Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med (2004) 7.62
Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ (2000) 6.10
Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med (1995) 5.24
Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol (1996) 3.82
Advanced atherosclerotic lesions in the innominate artery of the ApoE knockout mouse. Arterioscler Thromb Vasc Biol (2000) 2.77
C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol (1998) 2.60
Delayed lupus onset in (NZB x NZW)F1 mice expressing a human C-reactive protein transgene. Arthritis Rheum (2003) 2.53
Serum amyloid P-component is an acute-phase reactant in the mouse. Nature (1979) 2.49
Interactions of C-reactive protein with the complement system. I. Protamine-induced consumption of complement in acute phase sera. J Exp Med (1974) 2.47
C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation (2004) 2.43
Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem (1999) 2.35
Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein. J Exp Med (1982) 2.33
Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol (1999) 2.17
Oral infection with a periodontal pathogen accelerates early atherosclerosis in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol (2003) 2.17
Isolation of human C-reactive protein and serum amyloid P component. J Immunol Methods (1982) 2.15
Isolation of serum amyloid P-component (protein SAP) in the mouse. Immunology (1979) 2.07
C-reactive protein and cardiovascular disease: new insights from an old molecule. QJM (2003) 1.93
Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol (1997) 1.90
Risk factors for coronary heart disease and acute-phase proteins. A population-based study. Eur Heart J (1999) 1.87
Influenza infection exerts prominent inflammatory and thrombotic effects on the atherosclerotic plaques of apolipoprotein E-deficient mice. Circulation (2003) 1.72
Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation (2003) 1.72
Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in transgenic mice. J Immunol (1995) 1.61
Atherosclerotic plaque rupture in the apolipoprotein E knockout mouse. Atherosclerosis (2001) 1.59
Obesity is an important determinant of baseline serum C-reactive protein concentration in monozygotic twins, independent of genetic influences. Circulation (2004) 1.59
Male management: Coping with aggression problems in male laboratory mice. Lab Anim (2003) 1.53
Inducible and tissue-specific expression of human C-reactive protein in transgenic mice. EMBO J (1987) 1.51
Effects of sex and age on atherosclerosis and autoimmunity in apoE-deficient mice. Atherosclerosis (1999) 1.38
Possible protective role for C-reactive protein in atherogenesis: complement activation by modified lipoproteins halts before detrimental terminal sequence. Circulation (2004) 1.26
Cytomegalovirus infection increases development of atherosclerosis in Apolipoprotein-E knockout mice. Atherosclerosis (2001) 1.25
A fluorescent immunoassay for the quantification of C-reactive protein. J Immunol Methods (1978) 1.23
Differences in the acute phase responses of serum amyloid P-component (SAP) and C3 to injections of casein or bovine serum albumin in amyloid-susceptible and -resistant mouse strains. Clin Exp Immunol (1980) 1.23
Quantitative assessment of aortic atherosclerosis in APOE*3 Leiden transgenic mice and its relationship to serum cholesterol exposure. Arterioscler Thromb Vasc Biol (1996) 1.20
Isolation and study of murine C3. Immunology (1977) 1.13
Development of a new microparticle-enhanced turbidimetric assay for C-reactive protein with superior features in analytical sensitivity and dynamic range. J Clin Lab Anal (1998) 1.11
The pentraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes in vivo. J Clin Invest (1994) 1.11
Herpesvirus infection accelerates atherosclerosis in the apolipoprotein E-deficient mouse. Circulation (2000) 1.08
ApoE(-/-) mice develop atherosclerosis in the absence of complement component C5. Biochem Biophys Res Commun (2001) 1.04
Multicentre performance evaluation of the E170 module for modular analytics. Clin Chem Lab Med (2004) 1.03
Plasma protein acute-phase response in unstable angina is not induced by ischemic injury. Circulation (1996) 1.02
Inflammation and the onset of myocardial infarction. Ann Intern Med (1985) 1.01
Transfer of plasma lipoprotein components and of plasma proteins into aortas of cholesterol-fed rabbits. Molecular size as a determinant of plasma lipoprotein influx. Arteriosclerosis (1981) 0.98
Testosterone and IL-6 requirements for human C-reactive protein gene expression in transgenic mice. J Immunol (1998) 0.98
Chronic stress accelerates atherosclerosis in the apolipoprotein E deficient mouse. Stress (2003) 0.97
Circulating human C-reactive protein binds very low density lipoproteins. Clin Exp Immunol (1984) 0.96
Beyond cholesterol: the enigma of atherosclerosis revisited. Thromb Haemost (2004) 0.94
Human C-reactive protein does not protect against acute lipopolysaccharide challenge in mice. J Immunol (2003) 0.89
Effect of bacterial endotoxin on body temperature, plasma zinc and plasma concentrations of the acute-phase protein serum amyloid p component in mice. Br J Exp Pathol (1984) 0.84
Plasma protein insudation as an index of early coronary atherogenesis. Am J Pathol (1993) 0.83
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet (2002) 16.56
C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med (2004) 15.30
Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med (2007) 12.93
Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med (2003) 12.23
C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet (2009) 11.81
Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med (2006) 9.21
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet (2008) 8.73
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. AIDS (2003) 5.61
Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis (2005) 5.20
HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet (2006) 5.00
Natural history and outcome in systemic AA amyloidosis. N Engl J Med (2007) 4.54
Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med (2002) 4.47
Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS (2007) 4.40
Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care (2008) 4.10
Targeting C-reactive protein for the treatment of cardiovascular disease. Nature (2006) 4.07
Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ (2011) 3.65
Retraction of an interpretation. Lancet (2004) 3.55
Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS (2010) 3.47
Late diagnosis of HIV infection: epidemiological features, consequences and strategies to encourage earlier testing. J Acquir Immune Defic Syndr (2007) 3.40
Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol (2003) 2.74
Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil (2010) 2.70
Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation (2008) 2.64
Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis (2006) 2.55
IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology (2006) 2.54
Transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infections. AIDS (2005) 2.51
The late diagnosis and consequent short-term mortality of HIV-infected heterosexuals (England and Wales, 2000-2004). AIDS (2006) 2.42
A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS (2006) 2.35
Response to combination antiretroviral therapy: variation by age. AIDS (2008) 2.28
HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS (2008) 2.27
Infusion of pharmaceutical-grade natural human C-reactive protein is not proinflammatory in healthy adult human volunteers. Circ Res (2013) 2.26
Genetic effects on baseline values of C-reactive protein and serum amyloid a protein: a comparison of monozygotic and dizygotic twins. Clin Chem (2003) 2.15
HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. Eur J Neurol (2010) 2.06
Newly diagnosed HIV infections: review in UK and Ireland. BMJ (2005) 2.00
Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology (2008) 1.98
The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med (2005) 1.97
3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome. Lancet (2006) 1.97
Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ Res (2005) 1.91
Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. AIDS (2009) 1.90
Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. N Engl J Med (2015) 1.84
Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antivir Ther (2008) 1.83
No time to wait: how many HIV-infected homosexual men are diagnosed late and consequently die? (England and Wales, 1993-2002). AIDS (2005) 1.82
Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature (2010) 1.81
Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood (2002) 1.77
The association of HBV core promoter double mutations (A1762T and G1764A) with viral load differs between HBeAg positive and anti-HBe positive individuals: a longitudinal analysis. J Hepatol (2008) 1.76
Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS (2002) 1.74
Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. J Infect Dis (2004) 1.70
Beyond "cirrhosis": a proposal from the International Liver Pathology Study Group. Am J Clin Pathol (2012) 1.65
Spectroscopic photoacoustic imaging of lipid-rich plaques in the human aorta in the 740 to 1400 nm wavelength range. J Biomed Opt (2012) 1.62
When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies. AIDS (2003) 1.60
Prevalence of hepatitis C-related cirrhosis in elderly Asian patients infected in childhood. Clin Gastroenterol Hepatol (2005) 1.59
Obesity is an important determinant of baseline serum C-reactive protein concentration in monozygotic twins, independent of genetic influences. Circulation (2004) 1.59
Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl (2005) 1.58
Late diagnosis in the HAART era: proposed common definitions and associations with mortality. AIDS (2010) 1.57
The relationship between liver disease stage and liver fibrosis: a tangled web. Histopathology (2010) 1.56
Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy. Liver Transpl (2009) 1.55
HBV A1762T, G1764A mutations are a valuable biomarker for identifying a subset of male HBsAg carriers at extremely high risk of hepatocellular carcinoma: a prospective study. Am J Gastroenterol (2008) 1.53
Leucocyte cathepsin K affects atherosclerotic lesion composition and bone mineral density in low-density lipoprotein receptor deficient mice. Cardiovasc Res (2008) 1.47
Normal circulating serum amyloid P component concentration in systemic sclerosis. Arthritis Rheum (2007) 1.42
Theoretical rationale for the use of sequential single-drug antiretroviral therapy for treatment of HIV infection. AIDS (2003) 1.41
Complement C1q reduces early atherosclerosis in low-density lipoprotein receptor-deficient mice. Am J Pathol (2007) 1.36
Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers. AIDS (2013) 1.34
A systematic review of the quality of liver biopsy specimens. Am J Clin Pathol (2006) 1.34
A systematic study of the effect of physiological factors on beta2-microglobulin amyloid formation at neutral pH. Biochemistry (2006) 1.33
Inflammation and endothelial function: direct vascular effects of human C-reactive protein on nitric oxide bioavailability. Circulation (2005) 1.33
Human plasma fibrinogen is synthesized in the liver. Blood (2006) 1.27
Sexual transmission of hepatitis C in MSM may not be confined to those with HIV infection. J Infect Dis (2008) 1.26
Hereditary systemic amyloidosis due to Asp76Asn variant β2-microglobulin. N Engl J Med (2012) 1.26
Hepatitis B virus pre-S deletion mutations are a risk factor for hepatocellular carcinoma: a matched nested case-control study. J Gen Virol (2008) 1.26
Scoring of chronic hepatitis. Clin Liver Dis (2002) 1.25
Production of granulocyte colony-stimulating factor in the nonspecific acute phase response enhances host resistance to bacterial infection. J Immunol (2002) 1.25
Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE-/- mice. Atherosclerosis (2007) 1.24
Progression of fibrosis in untreated patients with hepatitis C virus infection. Liver (2002) 1.24
Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood (2005) 1.22